Suppr超能文献

上呼吸道炎症性疾病中的抗白三烯药物

Antileukotrienes in upper airway inflammatory diseases.

作者信息

Cingi Cemal, Muluk Nuray Bayar, Ipci Kagan, Şahin Ethem

机构信息

Department for ORL Head and Neck Surgery, Faculty of Medicine, Eskişehir Osmangazi University, Eskisehir, Turkey.

ENT Department, Eskisehir Osmangazi University, Eskisehir, Turkey.

出版信息

Curr Allergy Asthma Rep. 2015 Nov;15(11):64. doi: 10.1007/s11882-015-0564-7.

Abstract

Leukotrienes (LTs) are a family of inflammatory mediators including LTA4, LTB4, LTC4, LTD4, and LTE4. By competitive binding to the cysteinyl LT1 (CysLT1) receptor, LT receptor antagonist drugs, such as montelukast, zafirlukast, and pranlukast, block the effects of CysLTs, improving the symptoms of some chronic respiratory diseases, particularly bronchial asthma and allergic rhinitis. We reviewed the efficacy of antileukotrienes in upper airway inflammatory diseases. An update on the use of antileukotrienes in upper airway diseases in children and adults is presented with a detailed literature survey. Data on LTs, antileukotrienes, and antileukotrienes in chronic rhinosinusitis and nasal polyps, asthma, and allergic rhinitis are presented. Antileukotriene drugs are classified into two groups: CysLT receptor antagonists (zafirlukast, pranlukast, and montelukast) and LT synthesis inhibitors (5-lipoxygenase inhibitors such as zileuton, ZD2138, Bay X 1005, and MK-0591). CysLTs have important proinflammatory and profibrotic effects that contribute to the extensive hyperplastic rhinosinusitis and nasal polyposis (NP) that characterise these disorders. Patients who receive zafirlukast or zileuton tend to show objective improvements in, or at least stabilisation of, NP. Montelukast treatment may lead to clinical subjective improvement in NP. Montelukast treatment after sinus surgery can lead to a significant reduction in eosinophilic cationic protein levels in serum, with a beneficial effect on nasal and pulmonary symptoms and less impact in NP. Combined inhaled corticosteroids and long-acting β-agonists treatments are most effective for preventing exacerbations among paediatric asthma patients. Treatments with medium- or high-dose inhaled corticosteroids, combined inhaled corticosteroids and LT receptor antagonists, and low-dose inhaled corticosteroids have been reported to be equally effective. Antileukotrienes have also been reported to be effective for allergic rhinitis.

摘要

白三烯(LTs)是一类炎症介质,包括LTA4、LTB4、LTC4、LTD4和LTE4。通过与半胱氨酰白三烯1(CysLT1)受体竞争性结合,白三烯受体拮抗剂药物,如孟鲁司特、扎鲁司特和普仑司特,可阻断半胱氨酰白三烯(CysLTs)的作用,改善一些慢性呼吸道疾病的症状,尤其是支气管哮喘和过敏性鼻炎。我们综述了抗白三烯药物在上气道炎症性疾病中的疗效。通过详细的文献调查,介绍了抗白三烯药物在儿童和成人上气道疾病中的最新应用情况。列出了慢性鼻窦炎和鼻息肉、哮喘及过敏性鼻炎中有关白三烯、抗白三烯药物的数据。抗白三烯药物分为两类:CysLT受体拮抗剂(扎鲁司特、普仑司特和孟鲁司特)和白三烯合成抑制剂(5-脂氧合酶抑制剂,如齐留通、ZD2138、Bay X 1005和MK-0591)。CysLTs具有重要的促炎和促纤维化作用,可导致这些疾病所特有的广泛性增生性鼻窦炎和鼻息肉(NP)。接受扎鲁司特或齐留通治疗的患者NP往往会出现客观改善或至少病情稳定。孟鲁司特治疗可能会使NP的临床主观症状得到改善。鼻窦手术后使用孟鲁司特治疗可使血清嗜酸性阳离子蛋白水平显著降低,对鼻部和肺部症状有有益影响,对NP的影响较小。联合吸入糖皮质激素和长效β受体激动剂治疗对预防儿童哮喘患者病情加重最为有效。据报道,中、高剂量吸入糖皮质激素、联合吸入糖皮质激素和白三烯受体拮抗剂以及低剂量吸入糖皮质激素治疗效果相同。抗白三烯药物据报道对过敏性鼻炎也有效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验